Drug intelligence / Profile preview

belotecan + ifosfamide

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

Belotecan + ifosfamide is an investigational combination chemotherapy regimen consisting of belotecan, a camptothecin analog and topoisomerase I inhibitor, and ifosfamide, an alkylating agent. This combination has been studied in clinical trials for the treatment of small cell lung cancer (SCLC). Belotecan inhibits DNA topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing tumor cells. Ifosfamide acts as a cytotoxic alkylating agent that crosslinks DNA strands, thereby inhibiting DNA replication and transcription. The combination aims to enhance antitumor efficacy by targeting cancer cells through complementary mechanisms[1][2].

Targets

TOP1 (DNA Topoisomerase I)DNA

Beyond the preview

Go deeper on belotecan + ifosfamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on belotecan + ifosfamide.

Explore the full profile